ObsEva SA OBSEF

OBSEF Company Overview

ObsEva SA is a Switzerland-based biopharmaceutical company focused on developing therapies for women’s reproductive health and pregnancy-related conditions. The company historically concentrated on treatments addressing uterine fibroids, endometriosis, preterm labor, and assisted reproductive technologies. ObsEva operated within the biotechnology and specialty pharmaceutical industries, with its strategy centered on licensing, clinical development, and commercialization partnerships for late-stage reproductive medicine assets.

The company was founded in 2012 and established headquarters in Geneva, Switzerland. ObsEva became publicly listed on NASDAQ under the ticker “OBSV” before later trading in over-the-counter markets as OBSEF following financial and operational restructuring. Over time, the company evolved from a multi-asset women’s health developer into a more limited clinical-stage organization after discontinuation or divestment of several programs due to financing constraints and regulatory setbacks. Public filings and market disclosures indicate that ObsEva’s historical value proposition relied on targeting underserved reproductive health conditions with differentiated hormone-modulating therapies.